https://www.pharmaradar360.com/article/september-highlights-a-defined-path-from-enrollment-to-data-to-regulatory-submis-546ba70def50c57bPharmaRadar360en2026-09-23T16:54:55.000ZSeptember Highlights: A Defined Path from Enrollment to Data to Regulatory Submission, Medtronic & Orchestra at HRX, A Milestone Payment, Healthcare Investor Conferences and Morehttps://www.pharmaradar360.com/article/china-issues-new-guidelines-on-fentanyl-related-crimes-clarifies-sentencing-stan-d40ab24fc3aaf703PharmaRadar360en2026-09-23T15:51:00.000ZChina issues new guidelines on fentanyl-related crimes, clarifies sentencing standardshttps://www.pharmaradar360.com/article/pharmap-2027-addresses-the-future-of-pharmaceutical-manufacturing-and-packaging-a24f87902f85969aPharmaRadar360en2026-09-23T15:44:12.000ZPHARMAP 2027 Addresses the Future of Pharmaceutical Manufacturing and Packaginghttps://www.pharmaradar360.com/article/can-immunotherapy-stop-the-clock-on-type-1-diabetes-01c89bbc9df567f0PharmaRadar360en2026-09-23T15:42:04.000ZCan immunotherapy stop the clock on type 1 diabetes?https://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-aa00bf1f361ce5fePharmaRadar360en2026-09-23T15:41:26.000Z37,000 AI Agents Are Running a Virtual Biotech at Stanfordhttps://www.pharmaradar360.com/article/eli-lilly-vs-pfizer-in-2027-one-is-a-much-better-place-to-park-your-pharmaceutic-4de0a023ca1e4643PharmaRadar360en2026-09-23T15:32:00.000ZEli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Yearhttps://www.pharmaradar360.com/article/9-pharma-leaders-sound-alarm-bells-on-biotech-s-decline-in-europe-8cae6dd44987e769PharmaRadar360en2026-09-23T15:31:59.000Z9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europehttps://www.pharmaradar360.com/article/ubc-okanagan-boosts-biotech-growth-jobs-in-kelowna-b5445b438b22e3dfPharmaRadar360en2026-09-23T15:26:00.000ZUBC Okanagan Boosts Biotech Growth, Jobs in Kelownahttps://www.pharmaradar360.com/article/covid-19-vaccination-vaccine-product-information-2f002a54e328b7a9PharmaRadar360en2026-09-23T15:24:13.000ZCOVID-19 vaccination: vaccine product informationhttps://www.pharmaradar360.com/article/jaguar-health-plunges-59-and-viking-therapeuti-db83db73d7dc3b68PharmaRadar360en2026-09-23T15:14:26.000ZJaguar Health plunges 59% and Viking Therapeuti...https://www.pharmaradar360.com/article/petroliferos-lobo-and-oz-studio-expand-trace-from-petroleum-into-pharmaceutical-d8b3b5494ab74d32PharmaRadar360en2026-09-23T15:06:55.000ZPetrolíferos Lobo and Oz Studio Expand TRACE From Petroleum Into Pharmaceutical and Supplement Traceabilityhttps://www.pharmaradar360.com/article/new-safety-module-in-the-clinical-trials-information-system-ctis-50e683a4919aefcePharmaRadar360en2026-09-23T15:02:00.000ZNew Safety Module in the Clinical Trials Information System (CTIS)https://www.pharmaradar360.com/article/europe-s-pharma-chiefs-warn-bloc-is-losing-innovation-race-dd74789b50fb2c08PharmaRadar360en2026-09-23T14:56:17.000ZEurope’s Pharma Chiefs Warn Bloc is Losing Innovation Racehttps://www.pharmaradar360.com/article/students-fill-high-paying-biotech-jobs-7b177440d9c34a4ePharmaRadar360en2026-09-23T14:52:11.000ZStudents fill high-paying biotech jobshttps://www.pharmaradar360.com/article/expres2ion-biotech-holding-ab-exprs2-secures-sek-19-3m-to-13-exercise-1-1-b1ec93da641bbb8dPharmaRadar360en2026-09-23T14:50:00.000ZExpreS2ion Biotech Holding AB (EXPRS2) Secures ~SEK 19.3M; TO 13 Exercise 1.1%https://www.pharmaradar360.com/article/european-big-pharma-unites-amid-ringing-alarm-bells-of-continents-dominance-42c06e624a767769PharmaRadar360en2026-09-23T13:54:28.000ZEuropean big pharma unites amid ‘ringing alarm bells’ of continents dominancehttps://www.pharmaradar360.com/article/bit-bio-partners-with-miriamed-to-bring-human-cardiomyocytes-to-its-drug-discove-6dfc3ef16dd20840PharmaRadar360en2026-09-23T13:47:54.000ZBit.bio partners with Miriamed to bring human cardiomyocytes to its drug discovery portfoliohttps://www.pharmaradar360.com/article/enveda-reaps-311m-series-e-to-feed-ambition-to-become-a-household-name-f72260477437e222PharmaRadar360en2026-09-23T13:47:04.000ZEnveda reaps $311M series E to feed ambition to become a ‘household name’https://www.pharmaradar360.com/article/flagship-gets-a-pentagon-contract-fcb7bac7859a0771PharmaRadar360en2026-09-23T13:38:45.000ZFlagship gets a Pentagon contracthttps://www.pharmaradar360.com/article/maia-biotechnology-expands-pivotal-phase-3-thio-104-non-small-cell-lung-cancer-t-410cbc55b527a9d2PharmaRadar360en2026-09-23T13:32:07.000ZMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugalhttps://www.pharmaradar360.com/article/jedco-innovation-to-boost-jordan-s-pharmaceutical-industry-expansion-competitive-60088197bf5af4b5PharmaRadar360en2026-09-23T13:29:24.000ZJEDCO: Innovation to Boost Jordan’s Pharmaceutical Industry Expansion, Competitivenesshttps://www.pharmaradar360.com/article/public-mental-health-autumn-webinar-school-based-mental-health-interventions-9698cdb22343e0dcPharmaRadar360en2026-09-23T13:28:02.000ZPublic Mental Health Autumn Webinar: School-Based Mental Health Interventionshttps://www.pharmaradar360.com/article/q-a-why-ndc-12-readiness-has-to-happen-before-day-one-b1cd27b1952015f8PharmaRadar360en2026-09-23T13:26:33.000ZQ&A: Why NDC-12 Readiness Has to Happen Before Day Onehttps://www.pharmaradar360.com/article/about-30-000-new-lung-cancer-cases-occur-yearly-in-spain-and-portugal-a-trial-ha-0bd639da70000348PharmaRadar360en2026-09-23T13:17:00.000ZAbout 30,000 new lung cancer cases occur yearly in Spain and Portugal; a trial has approval to screen patients there.https://www.pharmaradar360.com/article/concord-biotech-announces-1-1-bonus-share-issue-shareholders-to-get-one-free-sha-e452dcfda4d71e2bPharmaRadar360en2026-09-23T13:15:17.000ZConcord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each held - CNBC TV18https://www.pharmaradar360.com/article/rbc-says-ai-weakness-appears-to-be-fueling-biotech-rally-f7ddd140c25173b3PharmaRadar360en2026-09-23T13:13:59.000ZRBC says AI weakness appears to be fueling biotech rallyhttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-phase-3-astra-trial-of-aurn001-for-cornea-d5b3dd232e1b81b4PharmaRadar360en2026-09-23T13:09:23.000ZAurion Biotech Completes Enrollment in Phase 3 ASTRA Trial of AURN001 for Corneal Edemahttps://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-d2d89fe7cfa4c511PharmaRadar360en2026-09-23T13:08:58.000ZEnveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Centuryhttps://www.pharmaradar360.com/article/sweden-a-powerhouse-for-early-stage-innovation-32336554ff8d853fPharmaRadar360en2026-09-23T13:06:41.000ZSweden, a Powerhouse for Early Stage Innovationhttps://www.pharmaradar360.com/article/maharashtra-fda-chief-tukaram-mundhe-welcomes-bollywood-actors-support-for-food-7704108b6ff5afbePharmaRadar360en2026-09-23T13:06:00.000ZMaharashtra FDA chief Tukaram Mundhe welcomes Bollywood actors' support for food safety crackdownhttps://www.pharmaradar360.com/article/new-yorkers-prescribed-generic-drugs-could-be-entitled-to-share-of-96m-settlemen-079f2f04be6ccf19PharmaRadar360en2026-09-23T13:05:58.000ZNew Yorkers Prescribed Generic Drugs Could Be Entitled To Share Of $96M Settlement: AGhttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-b-braun-melsungen-ag-meropenem-1000-mg-pow-c017a279be305219PharmaRadar360en2026-09-23T13:00:26.000ZClass 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/39https://www.pharmaradar360.com/article/two-men-joined-forces-at-a-biotech-firm-one-is-being-hailed-for-his-work-to-cure-b32648efcb588026PharmaRadar360en2026-09-23T13:00:00.000ZTwo Men Joined Forces at a Biotech Firm. One Is Being Hailed for His Work to Cure HIV. The Other Is Going to Prison.https://www.pharmaradar360.com/article/main-sequence-backs-dementia-biotech-kinoxis-in-a-9-25m-round-1e029c7e02718a39PharmaRadar360en2026-09-23T12:53:56.000ZMain Sequence backs dementia biotech Kinoxis in A$9.25M roundhttps://www.pharmaradar360.com/article/maharashtra-tukaram-mundhe-led-fda-expands-food-safety-drive-to-schools-festival-ff43b1c3c042f5f4PharmaRadar360en2026-09-23T12:52:54.000ZMaharashtra: Tukaram Mundhe-Led FDA Expands Food Safety Drive To Schools, Festivals, Pharmacies & Foodhttps://www.pharmaradar360.com/article/cphi-milan-2026-preview-key-themes-and-emerging-trends-64ad898e4b3525cePharmaRadar360en2026-09-23T12:33:06.000ZCPHI Milan 2026 preview: key themes and emerging trendshttps://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-game-biotech-volatility-f2eafaf137ceaf88PharmaRadar360en2026-09-23T12:33:00.000ZDCOY Stock Whipsaws As Traders Game Biotech Volatilityhttps://www.pharmaradar360.com/article/a-drug-formulation-designed-to-reach-lung-tumors-has-mexican-patent-protection-t-9a6226bbb164d9bePharmaRadar360en2026-09-23T12:29:49.000ZA drug formulation designed to reach lung tumors has Mexican patent protection through 2040.https://www.pharmaradar360.com/article/6-moonshot-biotech-stocks-that-offer-big-risks-bigger-rewards-2ec5afb22e0bf892PharmaRadar360en2026-09-23T12:28:00.000Z6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewardshttps://www.pharmaradar360.com/article/oppenheimer-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-d07bac4ace81e494PharmaRadar360en2026-09-23T12:27:08.000ZOppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)https://www.pharmaradar360.com/article/moleculin-nasdaq-mbrx-lowers-warrant-price-while-stating-it-needs-trial-funding-37feb91e0c967f74PharmaRadar360en2026-09-23T12:25:55.000ZMoleculin (NASDAQ: MBRX) lowers warrant price while stating it needs trial fundinghttps://www.pharmaradar360.com/article/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-liposomal-anna-72c1ed32316517e8PharmaRadar360en2026-09-23T12:25:00.000ZMoleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-900b781ebb8e9b5bPharmaRadar360en2026-09-23T12:19:55.000ZAurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunctionhttps://www.pharmaradar360.com/article/european-pharmaceutical-sector-faces-decline-amid-global-competition-87e90953660cdc78PharmaRadar360en2026-09-23T12:06:21.000ZEuropean Pharmaceutical Sector Faces Decline Amid Global Competitionhttps://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-dc35a2b891936318PharmaRadar360en2026-09-23T12:00:30.000ZEnveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Centuryhttps://www.pharmaradar360.com/article/williams-cystoscopic-injection-needle-6c20102f9f238606PharmaRadar360en2026-09-23T12:00:00.000ZWilliams Cystoscopic Injection Needlehttps://www.pharmaradar360.com/article/omniasecuretm-mri-surescantm-2d8833077cd38fa9PharmaRadar360en2026-09-23T12:00:00.000ZOmniaSecure™ MRI SureScan™https://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-target-biotech-volatility-4c2712f525e7e336PharmaRadar360en2026-09-23T11:48:00.000ZDCOY Stock Whipsaws As Traders Target Biotech Volatilityhttps://www.pharmaradar360.com/article/2026-1d5604d4a504007cPharmaRadar360en2026-09-23T11:39:17.000ZΓενόσημα Ιουλίου 2026_Τελικές Προτεινόμενες Τιμέςhttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-why-biotech-s-recovery-could-still-have-further-to-310d1862d2e9b283PharmaRadar360en2026-09-23T11:27:10.000ZThe Biotech Growth Trust plc – Why Biotech’s Recovery Could Still Have Further to Run (video)https://www.pharmaradar360.com/article/viking-s-vk2735-shows-durable-weight-loss-with-less-frequent-maintenance-dosing-03f08420126a796fPharmaRadar360en2026-09-23T11:23:18.000ZViking's VK2735 shows durable weight loss with less frequent maintenance dosinghttps://www.pharmaradar360.com/article/oppenheimer-initiates-collegium-pharmaceutical-stock-at-outperform-c9f41444cb0d0522PharmaRadar360en2026-09-23T11:19:54.000ZOppenheimer initiates Collegium Pharmaceutical stock at Outperformhttps://www.pharmaradar360.com/article/scientists-are-testing-an-unexpected-new-weapon-against-screwworm-7d6cd17f448fee72PharmaRadar360en2026-09-23T11:00:47.000ZScientists are testing an unexpected new weapon against screwwormhttps://www.pharmaradar360.com/article/ukhsa-expands-wastewater-surveillance-to-strengthen-early-warning-system-for-dan-cebf5a4b17395e76PharmaRadar360en2026-09-23T11:00:02.000ZUKHSA expands wastewater surveillance to strengthen ‘early warning system’ for dangerous pathogenshttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-b6711b307932a822PharmaRadar360en2026-09-23T11:00:00.000ZAurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunctionhttps://www.pharmaradar360.com/article/henlius-looks-to-us-biotech-for-global-tce-rights-in-amberstone-deal-61b48e357cb64d42PharmaRadar360en2026-09-23T10:35:09.000ZHenlius looks to US biotech for global TCE rights in Amberstone dealhttps://www.pharmaradar360.com/article/jefferies-raises-amgen-stock-price-target-on-drug-trial-success-cc7e529ee5fe6e74PharmaRadar360en2026-09-23T10:21:52.000ZJefferies raises Amgen stock price target on drug trial successhttps://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-christoph-weber-for-board-seat-eb5e783eba6901a0PharmaRadar360en2026-09-23T10:11:38.000ZRoche proposes former Takeda CEO Christoph Weber for board seathttps://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-and-amberstone-biosciences-inc-enter-collaboration-fc21a4575dc1493dPharmaRadar360en2026-09-23T10:05:54.000ZShanghai Henlius Biotech, Inc. And Amberstone Biosciences, Inc. Enter Collaboration And License Agreement For Two T Cell Engager Productshttps://www.pharmaradar360.com/article/ai-biotech-startup-enveda-doubles-in-value-to-2-billion-wsj-2a17d33df3769840PharmaRadar360en2026-09-23T10:03:47.000ZAI biotech startup Enveda doubles in value to $2 billion - WSJhttps://www.pharmaradar360.com/article/abortion-statistics-user-engagement-plan-65fe5013a86b6246PharmaRadar360en2026-09-23T10:00:04.000ZAbortion statistics user engagement planhttps://www.pharmaradar360.com/article/abortion-statistics-in-england-and-wales-62845a4d19ed888cPharmaRadar360en2026-09-23T10:00:04.000ZAbortion statistics in England and Waleshttps://www.pharmaradar360.com/article/exclusive-ai-biotech-enveda-doubles-in-value-to-2-billion-a869218d6b806c02PharmaRadar360en2026-09-23T10:00:00.000ZExclusive | AI Biotech Enveda Doubles in Value to $2 Billionhttps://www.pharmaradar360.com/article/jimmy-kimmel-trolls-trump-s-allies-with-parody-pharmaceutical-ad-b474764485d9f9c8PharmaRadar360en2026-09-23T09:59:51.000ZJimmy Kimmel trolls Trump's allies with parody pharmaceutical adhttps://www.pharmaradar360.com/article/polyurethane-tubing-for-biotech-market-to-2035-biopharma-capacity-expansion-driv-2c9779b6fa8fae8dPharmaRadar360en2026-09-23T09:46:23.000ZPolyurethane Tubing for Biotech Market To 2035: Biopharma Capacity Expansion Drives Growth - News and Statisticshttps://www.pharmaradar360.com/article/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-40671ca1388c0776PharmaRadar360en2026-09-23T09:42:10.000ZPharmaceutical Companies Push Trump Administration to Protect China Dealshttps://www.pharmaradar360.com/article/nine-european-pharma-chairs-warn-of-slow-agony-as-investment-slips-1254cc631db64b03PharmaRadar360en2026-09-23T09:22:06.000ZNine European pharma chairs warn of 'slow agony' as investment slipshttps://www.pharmaradar360.com/article/otsuka-and-ionis-report-positive-phase-iii-readout-for-ulefnersen-36ca2d60798ce8dfPharmaRadar360en2026-09-23T09:22:06.000ZOtsuka and Ionis report positive Phase III readout for ulefnersenhttps://www.pharmaradar360.com/article/drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis-treatments-ed6a223fc4d8d0a9PharmaRadar360en2026-09-23T09:15:45.000ZDrugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatmentshttps://www.pharmaradar360.com/article/doustdar-on-plunging-share-price-reflects-level-of-confidence-in-the-company-and-73e26491eface571PharmaRadar360en2026-09-23T09:04:22.000ZDoustdar on plunging share price: Reflects level of confidence in the company and its CEOhttps://www.pharmaradar360.com/article/field-safety-notices-14-to-18-september-2026-e1fc284848d2c91cPharmaRadar360en2026-09-23T09:03:48.000ZField Safety Notices: 14 to 18 September 2026https://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-d981698b76b6bbf6PharmaRadar360en2026-09-23T09:00:20.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/keep-britain-working-20e801e2a2496745PharmaRadar360en2026-09-23T08:58:51.000ZKeep Britain Workinghttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-23T08:56:55.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/fullgoal-fund-management-co-ltd-fullgoal-hang-seng-biotech-index-etf-159132-sz-i-566836e7c8e4c8f8PharmaRadar360en2026-09-23T08:56:19.000ZFullgoal Fund Management Co. Ltd - Fullgoal Hang Seng Biotech Index ETF (159132.SZ) income statementhttps://www.pharmaradar360.com/article/innovation-must-remain-at-the-heart-of-pandemic-prevention-preparedness-and-resp-3432662b985a1270PharmaRadar360en2026-09-23T08:22:29.000ZInnovation must remain at the heart of pandemic prevention, preparedness, and response, says pharma industryhttps://www.pharmaradar360.com/article/vaccine-update-issue-376-september-2026-d78aba8959192ee6PharmaRadar360en2026-09-23T08:19:03.000ZVaccine update: issue 376, September 2026https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-leaders-bfa3f2c240dbd84fPharmaRadar360en2026-09-23T08:18:48.000ZTop 10: Pharmaceutical Manufacturing Leadershttps://www.pharmaradar360.com/article/testo-at-cphi-2026-in-milan-digital-monitoring-for-the-pharmaceutical-industry-51206cd2f0198a2fPharmaRadar360en2026-09-23T08:00:00.000ZTesto at CPHI 2026 in Milan: digital monitoring for the pharmaceutical industryhttps://www.pharmaradar360.com/article/redweiler-480g-red-punch-redweiler-480g-orange-redweiler-480g-cola-tcm-120-mega-f98b8409bad1dccePharmaRadar360en2026-09-23T07:53:29.000ZΑπαγόρευση διάθεσης και διακίνησης των συμπληρωμάτων διατροφής REDWEILER 480G red punch, REDWEILER 480G orange, REDWEILER 480G cola, TCM 120 MEGA capshttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662PharmaRadar360en2026-09-23T07:48:01.000ZAnnual flu programmehttps://www.pharmaradar360.com/article/medienmitteilung-die-bevolkerung-erwartet-einen-besseren-zugang-zu-innovativen-m-f83c269f70b8021fPharmaRadar360en2026-09-23T07:14:59.000ZMedienmitteilung: Die Bevölkerung erwartet einen besseren Zugang zu innovativen Medikamentenhttps://www.pharmaradar360.com/article/anaconda-biomed-snares-56m-in-funding-for-endovascular-tech-ec4619246ad794d9PharmaRadar360en2026-09-23T07:00:00.000ZAnaconda Biomed snares $56M in funding for endovascular techhttps://www.pharmaradar360.com/article/fda-lifts-clinical-hold-on-simufilam-for-tsc-related-epilepsy-study-eca3143a8c42883fPharmaRadar360en2026-09-23T06:54:46.000ZFDA Lifts Clinical Hold on Simufilam for TSC-Related Epilepsy Studyhttps://www.pharmaradar360.com/article/barzolvolimab-meets-all-primary-and-key-secondary-endpoints-in-phase-3-csu-trial-aaa1c6a5ed41a8daPharmaRadar360en2026-09-23T06:53:08.000ZBarzolvolimab Meets All Primary and Key Secondary Endpoints in Phase 3 CSU Trialshttps://www.pharmaradar360.com/article/cbl-514-meets-primary-endpoint-in-phase-2-dercum-s-disease-trial-4aa1315c77b554dcPharmaRadar360en2026-09-23T06:53:08.000ZCBL-514 Meets Primary Endpoint in Phase 2 Dercum’s Disease Trialhttps://www.pharmaradar360.com/article/roche-s-sefaxersen-meets-primary-endpoint-in-phase-3-igan-study-8446d6133f8aa4caPharmaRadar360en2026-09-23T06:53:08.000ZRoche’s Sefaxersen Meets Primary Endpoint in Phase 3 IgAN Studyhttps://www.pharmaradar360.com/article/denmark-s-central-bank-sees-4-gdp-growth-in-2026-boosted-by-pharmaceutical-indus-ae01f315cf303771PharmaRadar360en2026-09-23T06:44:25.000ZDenmark's central bank sees 4% GDP growth in 2026, boosted by pharmaceutical industryhttps://www.pharmaradar360.com/article/wednesday-newspaper-round-up-state-pension-pharmaceutical-companies-bmw-22f669ea94e5958fPharmaRadar360en2026-09-23T06:05:54.000ZWednesday newspaper round-up: state pension, pharmaceutical companies, BMWhttps://www.pharmaradar360.com/article/a-kidney-disease-can-progress-to-kidney-failure-in-up-to-half-of-patients-within-b504c1b48ca0f4bdPharmaRadar360en2026-09-23T05:53:44.000ZA kidney disease can progress to kidney failure in up to half of patients within 20 years. Ionis' drug met its trial goal.https://www.pharmaradar360.com/article/argenx-arrowhead-incyte-and-other-moonshot-biotech-stocks-to-watch-6bcfcd137294b001PharmaRadar360en2026-09-23T05:45:00.000ZArgenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watchhttps://www.pharmaradar360.com/article/blood-stained-ice-found-at-gallops-in-mumbai-restaurant-deepika-padukone-hosted-d7c8d4be6fe7ad46PharmaRadar360en2026-09-23T05:41:05.000ZBlood Stained Ice Found At Gallops In Mumbai, Restaurant Deepika Padukone Hosted Her Fanshttps://www.pharmaradar360.com/article/hhs-unveils-new-initiatives-to-reduce-animal-testing-in-drug-development-dcfb867919371bddPharmaRadar360en2026-09-23T05:18:52.000ZHHS unveils new initiatives to reduce animal testing in drug developmenthttps://www.pharmaradar360.com/article/positive-interim-data-shows-roche-s-sefaxersen-significantly-reduces-proteinuria-18f5014a922c38adPharmaRadar360en2026-09-23T05:15:00.000ZPositive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)https://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-for-board-seat-904ade392ec97c62PharmaRadar360en2026-09-23T05:12:00.000ZRoche proposes former Takeda CEO for board seathttps://www.pharmaradar360.com/article/pfizer-india-speaks-up-after-karnataka-fda-crackdown-says-patient-safety-is-top-2d42ea33dec63e93PharmaRadar360en2026-09-23T05:07:00.000ZPfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priorityhttps://www.pharmaradar360.com/article/change-in-roche-s-board-of-directors-3f66dadd4f0ce683PharmaRadar360en2026-09-23T05:00:00.000ZChange in Roche’s Board of Directorshttps://www.pharmaradar360.com/article/how-is-incyte-s-stock-performance-compared-to-other-biotech-stocks-217f74a05b95f6c6PharmaRadar360en2026-09-23T04:53:05.000ZHow Is Incyte’s Stock Performance Compared to Other Biotech Stocks?https://www.pharmaradar360.com/article/how-is-incyte-s-stock-performance-compared-to-other-biotech-stocks-31a60ba7548325a7PharmaRadar360en2026-09-23T04:53:00.000ZHow Is Incyte’s Stock Performance Compared to Other Biotech Stocks?https://www.pharmaradar360.com/article/varda-space-industries-signs-steve-layne-as-chief-revenue-officer-and-aaron-hube-c7f0826d164cee9bPharmaRadar360en2026-09-23T04:37:11.000ZVarda Space Industries Signs Steve Layne as Chief Revenue Officer and Aaron Huber as Chief Financial Officerhttps://www.pharmaradar360.com/article/china-s-surging-biotech-sector-represents-both-competition-and-lifeline-for-the-3c127d71cc0c9a1ePharmaRadar360en2026-09-23T04:23:05.000ZChina’s surging biotech sector represents both competition and lifeline for the UShttps://www.pharmaradar360.com/article/china-clinical-trials-give-biotech-edge-us-concerns-grow-news-and-statistics-0f3c5f350061d556PharmaRadar360en2026-09-23T04:03:05.000ZChina Clinical Trials Give Biotech Edge; US Concerns Grow - News and Statisticshttps://www.pharmaradar360.com/article/biotech-is-one-area-where-the-us-can-afford-to-let-china-flourish-804a8a8a2ecb3155PharmaRadar360en2026-09-23T04:00:29.000ZBiotech is one area where the US can afford to let China flourishhttps://www.pharmaradar360.com/article/guggenheim-names-top-stock-pick-in-biotech-sector-b71fce6a39b3f0f4PharmaRadar360en2026-09-23T03:49:51.000ZGuggenheim Names Top Stock Pick in Biotech Sectorhttps://www.pharmaradar360.com/article/pca-girls-varsity-volleyball-vs-biotech-senior-32c8f64109110091PharmaRadar360en2026-09-23T03:45:35.000ZPCA Girls Varsity Volleyball vs. BioTECH Seniorhttps://www.pharmaradar360.com/article/a-share-market-update-pharmaceutical-stocks-surge-broadly-cansino-biologics-rise-8cc39d37a45eb156PharmaRadar360en2026-09-23T03:40:14.000ZA-Share Market Update: Pharmaceutical Stocks Surge Broadly; CanSino Biologics Rises Over 6%, Joinn Laboratories Up More Than 5%https://www.pharmaradar360.com/article/tailwind-biotech-wins-dkk-0-7m-innobooster-grant-9b2a13b8bb0fe6d2PharmaRadar360en2026-09-23T03:11:51.000ZTailwind Biotech wins DKK 0.7m Innobooster granthttps://www.pharmaradar360.com/article/karnataka-fake-drug-case-pfizer-issues-statement-after-fda-revokes-licenses-of-1-21bf72b4a7e780a2PharmaRadar360en2026-09-23T03:05:25.000ZKarnataka fake drug case: Pfizer issues statement after FDA revokes licenses of 16 pharmacieshttps://www.pharmaradar360.com/article/better-healthcare-etf-invesco-s-biotech-focused-ibbq-vs-ishares-broad-iyh-cf62d79b13533fb7PharmaRadar360en2026-09-23T03:04:00.000ZBetter Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYHhttps://www.pharmaradar360.com/article/dementia-biotech-kinoxis-raises-6-75-million-with-a-2-5m-grant-as-cherry-on-top-75874c1badfd9fddPharmaRadar360en2026-09-23T02:44:01.000ZDementia biotech Kinoxis raises $6.75 million with a $2.5m grant as cherry on tophttps://www.pharmaradar360.com/article/jeil-pharmaceutical-s-onconic-begins-phase-3-trial-in-china-for-jaqubo-injectabl-fc3a04ac114cee7ePharmaRadar360en2026-09-23T02:40:06.000ZJeil Pharmaceutical's Onconic Begins Phase 3 Trial in China for Jaqubo Injectable, Secures $1 Million Milestonehttps://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-4359a68ab4882f23PharmaRadar360en2026-09-23T02:20:02.000ZThe drugs and devices have been on the market for years, but FDA-ordered studies still aren't donehttps://www.pharmaradar360.com/article/mumbai-fda-suspends-five-food-licences-after-finding-fake-ghee-cockroaches-blood-89c6ba90f7452325PharmaRadar360en2026-09-23T02:02:00.000ZMumbai FDA suspends five food licences after finding fake ghee, cockroaches, blood stainshttps://www.pharmaradar360.com/article/are-clinical-trials-about-to-become-a-new-front-in-the-us-china-biotech-race-4d06a653e66fe2bdPharmaRadar360en2026-09-23T02:00:09.000ZAre clinical trials about to become a new front in the US-China biotech race?https://www.pharmaradar360.com/article/pharmac-opens-recruitment-for-new-community-and-patient-advisory-committee-2a31f0e2b8d9a966PharmaRadar360en2026-09-23T02:00:00.000ZPharmac opens recruitment for new Community and Patient Advisory Committeehttps://www.pharmaradar360.com/article/onconic-s-zastaprazan-enters-phase-3-injectable-trial-in-china-c9376c3ab0540be3PharmaRadar360en2026-09-23T01:53:45.000ZOnconic’s zastaprazan enters phase 3 injectable trial in Chinahttps://www.pharmaradar360.com/article/pfizer-says-patient-safety-top-priority-amid-karnataka-fake-drug-probe-6fdf8d6d60f6d15cPharmaRadar360en2026-09-23T01:52:19.000ZPfizer Says Patient Safety Top Priority Amid Karnataka Fake Drug Probehttps://www.pharmaradar360.com/article/young-discusses-national-security-threats-at-fdd-5b739c7bae264418PharmaRadar360en2026-09-23T00:35:41.000ZYoung Discusses National Security Threats at FDDhttps://www.pharmaradar360.com/article/onconic-therapeutics-launches-phase-3-clinical-trial-for-zaqubo-injectable-in-ch-5441eaf5cd51f86aPharmaRadar360en2026-09-23T00:14:14.000ZOnconic Therapeutics Launches Phase 3 Clinical Trial for "Zaqubo" Injectable in Chinahttps://www.pharmaradar360.com/article/onconic-advances-ja-q-bo-in-china-as-phase-3-injection-starts-royalties-rise-cho-b856b83f3cc2b983PharmaRadar360en2026-09-23T00:10:00.000ZOnconic advances Ja Q Bo in China as phase 3 injection starts, royalties rise - CHOSUNBIZhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-16511f0f2ac5ad4fPharmaRadar360en2026-09-23T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-01b3e887f7dcead6PharmaRadar360en2026-09-23T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-4f5db2d73dc985cfPharmaRadar360en2026-09-23T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-10eeac13aab4c900PharmaRadar360en2026-09-23T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f0eb7c639e6b7279PharmaRadar360en2026-09-23T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5670169091ce7e56PharmaRadar360en2026-09-23T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-eb184b78eb884466PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a093b591c8c1e790PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a5a2a3d18b030167PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-d97c25ec03b97152PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a92fc304b3f252b9PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-735fad2b7cd0513dPharmaRadar360en2026-09-23T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-feeaac083dd2ed3bPharmaRadar360en2026-09-23T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-829dd417dc97be75PharmaRadar360en2026-09-23T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-96e00503aecd8ab9PharmaRadar360en2026-09-23T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/patient-protection-and-affordable-care-act-temporary-moratoria-on-certain-agent-5d843f42db06f8b8PharmaRadar360en2026-09-23T00:00:00.000ZPatient Protection and Affordable Care Act; Temporary Moratoria on Certain Agent and Broker Registration To Participate in the Exchangeshttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-9d0893d801a68de3PharmaRadar360en2026-09-23T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-neurological-disorders-and-stroke-notice-of-closed-meeting-1fac41b8e10220fbPharmaRadar360en2026-09-23T00:00:00.000ZNational Institute of Neurological Disorders and Stroke; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-bc642d60aa107458PharmaRadar360en2026-09-23T00:00:00.000ZGovernment-Owned Inventions; Availability for Licensinghttps://www.pharmaradar360.com/article/sanjay-kumar-final-debarment-order-b205422749fd0e88PharmaRadar360en2026-09-23T00:00:00.000ZSanjay Kumar: Final Debarment Orderhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-4-hydroxy-n-n-diisopropyltryptam-4e3caa3036ced2d5PharmaRadar360en2026-09-23T00:00:00.000ZSchedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule Ihttps://www.pharmaradar360.com/article/carson-valley-health-becomes-cleveland-clinic-connected-member-174093ab24c60298PharmaRadar360en2026-09-23T00:00:00.000ZCarson Valley Health Becomes Cleveland Clinic Connected Memberhttps://www.pharmaradar360.com/article/ionis-pharmaceuticals-phase-3-kidney-trial-meets-proteinuria-endpoint-a1f79eed08f46dc9PharmaRadar360en2026-09-23T00:00:00.000ZIonis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpointhttps://www.pharmaradar360.com/article/clinical-and-biochemical-responses-to-sglt2-sodium-glucose-cotransporter-2-inhib-7adc369689ad7377PharmaRadar360en2026-09-23T00:00:00.000ZClinical and Biochemical Responses to SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors in Patients With Rheumatic Heart Disease and Heart Failurehttps://www.pharmaradar360.com/article/digital-blueprint-to-traditional-craftsmanship-rehabilitation-of-atraumatic-maxi-b15c1c90f65e1e61PharmaRadar360en2026-09-23T00:00:00.000ZDigital Blueprint to Traditional Craftsmanship: Rehabilitation of aTraumatic Maxillary Defect with a Definitive Obturator - A Case Reporthttps://www.pharmaradar360.com/article/coping-strategies-among-early-phase-cancer-clinical-trial-participants-6d40b1b740992c12PharmaRadar360en2026-09-23T00:00:00.000ZCoping Strategies Among Early-Phase Cancer Clinical Trial Participantshttps://www.pharmaradar360.com/article/peer-review-report-for-impact-of-pharmacist-involvement-in-antimicrobial-steward-b6da4337dc8c16fcPharmaRadar360en2026-09-23T00:00:00.000ZPeer Review Report For: Impact of Pharmacist Involvement in Antimicrobial Stewardship Programs on Clinical Outcome and Antibiotic Utilization in Intensive Care Unit: A Systematic Review and Meta-Analysis [version 1; peer review: 1 not approved]https://www.pharmaradar360.com/article/kidney-transplantation-in-patients-over-80-years-of-age-clinical-opportunity-eth-609ac733fe0515e3PharmaRadar360en2026-09-23T00:00:00.000ZKidney transplantation in patients over 80 years of age: clinical opportunity, ethical controversy, and the need for better selectionhttps://www.pharmaradar360.com/article/trefoil-technique-in-cryoballoon-isolation-of-the-left-common-pulmonary-vein-tru-9ab9b4bb159c12bfPharmaRadar360en2026-09-23T00:00:00.000Z«Trefoil» technique in cryoballoon isolation of the left common pulmonary vein trunk: clinical efficacy and anatomical predictorshttps://www.pharmaradar360.com/article/the-effect-of-a-fortified-date-bar-on-perceived-stress-and-morning-salivary-cort-795cb59bd9f91736PharmaRadar360en2026-09-23T00:00:00.000ZThe Effect of a Fortified Date Bar on Perceived Stress and Morning Salivary Cortisol in Female Students: A Pilot Randomized Controlled Trialhttps://www.pharmaradar360.com/article/neck-disability-associated-factors-and-quality-of-life-among-physiotherapists-in-49a201e66e78e7ebPharmaRadar360en2026-09-23T00:00:00.000ZNeck Disability, Associated Factors, and Quality of Life Among Physiotherapists in Saudi Arabiahttps://www.pharmaradar360.com/article/postoperative-c-reactive-protein-as-a-marker-of-the-early-inflammatory-response-875ae85d2ce71266PharmaRadar360en2026-09-23T00:00:00.000ZPostoperative C-Reactive Protein as a Marker of the Early Inflammatory Response in Robotic Versus Laparoscopic Minimally Invasive Surgery for Endometrial Cancer: A Propensity Score-Matched Analysishttps://www.pharmaradar360.com/article/short-term-safety-of-gastric-endoscopic-submucosal-dissection-in-patients-aged-8-4db1fa7ffa8f382bPharmaRadar360en2026-09-23T00:00:00.000ZShort-Term Safety of Gastric Endoscopic Submucosal Dissection in Patients Aged 80 Years or Older Under a Standardized Inpatient Post-Procedural Surveillance Pathway: Data from a 13-Year Real-World Cohort Studyhttps://www.pharmaradar360.com/article/a-multidimensional-assessment-of-cardiometabolic-risk-in-asian-americans-with-ch-03ad6b21bec4495cPharmaRadar360en2026-09-23T00:00:00.000ZA Multidimensional Assessment of Cardiometabolic Risk in Asian Americans with Chronic Hepatitis B Using the All of Us Datasetshttps://www.pharmaradar360.com/article/general-hiv-related-knowledge-and-attitudes-among-nurses-and-nursing-students-a-c6efa7106a99e37cPharmaRadar360en2026-09-23T00:00:00.000ZGeneral HIV-Related Knowledge and Attitudes Among Nurses and Nursing Students: A Systematic Review and Meta-Analysis with Narrative Synthesis of Clinical Practices (2011–2026)https://www.pharmaradar360.com/article/cannabinoids-in-diabetes-integrating-scientometric-trends-with-mechanistic-pharm-39278e405c2b26f7PharmaRadar360en2026-09-23T00:00:00.000ZCannabinoids in Diabetes: Integrating Scientometric Trends with Mechanistic, Pharmacokinetic, and Clinical Evidencehttps://www.pharmaradar360.com/article/integrative-analysis-of-atp2b4-expression-and-its-clinical-and-molecular-associa-930117645916a86dPharmaRadar360en2026-09-23T00:00:00.000ZIntegrative Analysis of ATP2B4 Expression and Its Clinical and Molecular Associations in Colorectal Cancerhttps://www.pharmaradar360.com/article/beyond-acquisition-quantifying-the-annual-carrying-cost-of-long-term-biospecimen-b9123924b47e7a6cPharmaRadar360en2026-09-23T00:00:00.000ZBeyond Acquisition: Quantifying the Annual Carrying Cost of Long-Term Biospecimen Storagehttps://www.pharmaradar360.com/article/paraprobiotics-and-postbiotics-from-mechanistic-evidence-to-food-applications-an-8f9399cd6bdd47ccPharmaRadar360en2026-09-23T00:00:00.000ZParaprobiotics and postbiotics: from mechanistic evidence to food applications and clinical translationhttps://www.pharmaradar360.com/article/editorial-explainable-artificial-intelligence-for-trustworthy-and-human-centric-ac82feba19738eaaPharmaRadar360en2026-09-23T00:00:00.000ZEditorial: Explainable artificial intelligence for trustworthy and human-centric healthcare: methods, evaluation, and clinical impacthttps://www.pharmaradar360.com/article/association-between-role-stress-and-job-burnout-among-clinical-research-nurses-a-b5aa08fccae4bfd4PharmaRadar360en2026-09-23T00:00:00.000ZAssociation between role stress and job burnout among clinical research nurses: a cross-sectional study in Chinahttps://www.pharmaradar360.com/article/therapist-self-report-reliability-and-accuracy-in-individual-vs-conjoint-systemi-e555b020dd335eddPharmaRadar360en2026-09-23T00:00:00.000ZTherapist self-report reliability and accuracy in individual vs. conjoint systemic family therapy sessions: implications for clinical monitoringhttps://www.pharmaradar360.com/article/optimal-prophylaxis-for-perioperative-drug-induced-delayed-neurocognitive-recove-5ca2615ca4e7f295PharmaRadar360en2026-09-23T00:00:00.000ZOptimal prophylaxis for perioperative drug-induced delayed neurocognitive recovery: a Bayesian network meta-analysis of 18 interventions with mechanism-based stratificationhttps://www.pharmaradar360.com/article/short-term-clinical-outcomes-associated-with-a-standardized-multicomponent-facia-e1801e946690bdbbPharmaRadar360en2026-09-23T00:00:00.000ZShort-term clinical outcomes associated with a standardized multicomponent facial rehabilitation program in acute or early-subacute peripheral facial nerve palsy: a prospective controlled cohort studyhttps://www.pharmaradar360.com/article/efficacy-of-anticoagulation-therapy-in-elderly-patients-with-clinically-diagnose-de416e1a65baf3d8PharmaRadar360en2026-09-23T00:00:00.000ZEfficacy of anticoagulation therapy in elderly patients with clinically diagnosed Alzheimer’s disease and atrial fibrillation: a clinical outcomes studyhttps://www.pharmaradar360.com/article/a-multimodal-machine-learning-diagnostic-model-for-alzheimer-s-disease-integrati-226cd8e46b6e3b46PharmaRadar360en2026-09-23T00:00:00.000ZA multimodal machine-learning diagnostic model for Alzheimer’s disease: integrating OCTA-derived retinal microvascular features and clinical variableshttps://www.pharmaradar360.com/article/biological-characterization-of-a-clinical-human-adenovirus-type-3-isolate-with-o-cdfc8156c517f734PharmaRadar360en2026-09-23T00:00:00.000ZBiological characterization of a clinical human adenovirus type 3 isolate with oncolytic potentialhttps://www.pharmaradar360.com/article/a-retrospective-cohort-study-predictive-nomogram-for-clinical-pregnancy-outcomes-3525205333fa2902PharmaRadar360en2026-09-23T00:00:00.000ZA retrospective cohort study: predictive nomogram for clinical pregnancy outcomes after intrauterine inseminationhttps://www.pharmaradar360.com/article/clinical-impact-of-early-enteral-nutrition-support-on-gastrointestinal-function-abe6b8b27c7ff208PharmaRadar360en2026-09-23T00:00:00.000ZClinical impact of early enteral nutrition support on gastrointestinal function, nutritional status, liver function, and immune function in liver cancer patientshttps://www.pharmaradar360.com/article/editorial-cellular-metabolism-the-immune-system-and-oncogenesis-opportunities-fo-f6f882b45b14e4b6PharmaRadar360en2026-09-23T00:00:00.000ZEditorial: Cellular metabolism, the immune system, and oncogenesis: opportunities for drug discovery and developmenthttps://www.pharmaradar360.com/article/clinical-and-epidemiological-profile-of-hospitalized-patients-with-leptospirosis-b7104dcb13cec58bPharmaRadar360en2026-09-23T00:00:00.000ZClinical and epidemiological profile of hospitalized patients with leptospirosis: a cross-sectional study in Durán, Ecuador, 2023https://www.pharmaradar360.com/article/metabolic-and-anthropometric-predictors-of-paediatric-metabolic-steatotic-liver-c04828fdbc62dda2PharmaRadar360en2026-09-23T00:00:00.000ZMetabolic and Anthropometric Predictors of Paediatric Metabolic Steatotic Liver Disease: Development of a Clinical Risk Prediction Modelhttps://www.pharmaradar360.com/article/safety-and-efficacy-of-whole-body-chlorhexidine-gluconate-cleansingwith-or-witho-bf1520c4fa2ebd4fPharmaRadar360en2026-09-23T00:00:00.000ZSafety and efficacy of whole-body chlorhexidine gluconate cleansingwith or without emollient in hospitalised neonates (NeoCHG): Amulticentre, randomised, open-label, factorial pilot trialhttps://www.pharmaradar360.com/article/uptake-barriers-and-facilitators-of-open-science-in-clinical-psychology-findings-e79006e53d98c6dePharmaRadar360en2026-09-23T00:00:00.000ZUptake, Barriers, and Facilitators of Open Science in Clinical Psychology: Findings from an Exploratory Survey in German-speaking Countrieshttps://www.pharmaradar360.com/article/pharmaceutical-care-contributes-to-tuberculosis-treatment-adherence-and-drug-saf-c97458518d1fd4b2PharmaRadar360en2026-09-23T00:00:00.000ZPharmaceutical Care Contributes to Tuberculosis Treatment Adherence and Drug Safety in Indonesia: A Systematic Reviewhttps://www.pharmaradar360.com/article/a-review-of-nanostructured-lipid-carriers-nlcs-and-their-applications-in-pharmac-4190dcc03c58cab9PharmaRadar360en2026-09-23T00:00:00.000ZA Review of Nanostructured Lipid Carriers (NLCs) and Their Applications in Pharmaceuticals and Cosmeticshttps://www.pharmaradar360.com/article/development-and-optimization-of-an-rt-qpcr-assay-for-determining-mirna-1202-expr-f465d5014a63c6ebPharmaRadar360en2026-09-23T00:00:00.000ZDevelopment and Optimization of an RT-qPCR Assay for Determining miRNA-1202 Expression Levels in Human Blood Sampleshttps://www.pharmaradar360.com/article/addictive-escapism-in-the-context-of-fragmentation-of-value-semantic-space-drug-39c30a45b7c82bb5PharmaRadar360en2026-09-23T00:00:00.000ZAddictive Escapism in the Context of Fragmentation of Value-Semantic Space: Drug Addiction as a Postmodern Marker of Modern Youth Alienationhttps://www.pharmaradar360.com/article/peer-review-report-for-effect-of-a-community-based-intervention-for-cardiovascul-bffd3e087f4f828cPharmaRadar360en2026-09-23T00:00:00.000ZPeer Review Report For: Effect of a community-based intervention for cardiovascular risk factor control on stroke mortality in rural Gadchiroli, India: a cluster-randomised controlled trial [version 2; peer review: 2 approved, 1 approved with reservations]https://www.pharmaradar360.com/article/impact-of-timing-of-presentation-and-laparoscopic-findings-on-clinical-outcomes-99b32a220658c2efPharmaRadar360en2026-09-23T00:00:00.000ZImpact of Timing of Presentation and Laparoscopic Findings on Clinical Outcomes in Penetrating Abdominal Trauma: A Comparative Cohort Studyhttps://www.pharmaradar360.com/article/the-aimsi-protocol-study-protocol-of-a-randomized-double-blind-non-inferiority-c-0d2f973c86632267PharmaRadar360en2026-09-23T00:00:00.000ZThe AIMSI protocol: study protocol of a randomized, double-blind, non-inferiority clinical trial in dermocosmetics dedicated to atopic dermatitis (Lipikar®, La Roche-Posay vs. Relipid®, NEUTRADERM)https://www.pharmaradar360.com/article/a-four-tier-anti-hcv-hcv-rna-interpretation-grid-for-risk-selected-clinical-popu-0462e6238c73bb27PharmaRadar360en2026-09-23T00:00:00.000ZA four-tier anti-HCV / HCV-RNA interpretation grid for risk-selected clinical populations: a Bayesian sensitivity analysis defining its valid operating rangehttps://www.pharmaradar360.com/article/immediate-analgesic-effect-of-cheek-acupuncture-vs-etoricoxib-for-patients-with-1f433045c616e8d5PharmaRadar360en2026-09-23T00:00:00.000ZImmediate analgesic effect of cheek acupuncture vs etoricoxib for patients with acute gouty flare: a randomized controlled trialhttps://www.pharmaradar360.com/article/recombinase-polymerase-amplification-coupled-with-crispr-cas12a-for-rapid-detect-9088f98caabcd613PharmaRadar360en2026-09-23T00:00:00.000ZRecombinase Polymerase Amplification Coupled with CRISPR-Cas12a for Rapid Detection of Ciprofloxacin-Resistance Mutations in Clinical Urinary Isolateshttps://www.pharmaradar360.com/article/polygenic-risk-score-enhances-comprehensive-breast-cancer-risk-assessment-and-mo-f105e2006792438ePharmaRadar360en2026-09-23T00:00:00.000ZPolygenic Risk Score Enhances Comprehensive Breast Cancer Risk Assessment and Modifies Clinical Actionability in Carriers of a Pathogenic Varianthttps://www.pharmaradar360.com/article/treatment-status-influences-circulating-microrna-expression-and-their-clinical-a-330230b34efa50aePharmaRadar360en2026-09-23T00:00:00.000ZTreatment status influences circulating microRNA expression and their clinical and radiological associations in multiple sclerosishttps://www.pharmaradar360.com/article/comparison-of-clinical-characteristics-species-composition-and-antimicrobial-res-ad48db0c75ecfcadPharmaRadar360en2026-09-23T00:00:00.000ZComparison of clinical characteristics, species composition and antimicrobial resistance in extrapulmonary nontuberculous mycobacteria with or without HIV co-infectionhttps://www.pharmaradar360.com/article/cell-free-therapies-emerging-applications-of-extracellular-vesicles-and-secretom-0eb0c307fb10fd9dPharmaRadar360en2026-09-23T00:00:00.000ZCell-free therapies: Emerging applications of extracellular vesicles and secretomes in regenerative medicinehttps://www.pharmaradar360.com/article/legal-organizational-and-financial-mechanisms-for-providing-medicines-not-includ-adcb8486b171831bPharmaRadar360en2026-09-23T00:00:00.000ZLegal, organizational and financial mechanisms for providing medicines not included in the list of vital and essential drugs in the State guaranteed free medical care program for citizens (using anticancer drug therapy as an example)https://www.pharmaradar360.com/article/leveraging-long-read-sequencing-to-bridge-the-diagnostic-and-equity-gaps-in-diff-e2cbefef207ca413PharmaRadar360en2026-09-23T00:00:00.000ZLeveraging Long-Read Sequencing to Bridge the Diagnostic and Equity Gaps in Differences of Sex Development (DSD)https://www.pharmaradar360.com/article/letter-to-the-editor-from-y-lmaz-et-al-the-free-t3-free-t4-ratio-predicts-relaps-73b9efa36fc223a3PharmaRadar360en2026-09-23T00:00:00.000ZLetter to the Editor from Yılmaz et al.: “The Free T3/Free T4 Ratio Predicts Relapse After Antithyroid Drug Withdrawal in Pediatric Autoimmune Hyperthyroidism”https://www.pharmaradar360.com/article/dna-methylation-dysregulation-in-ebv-associated-lymphoproliferative-disorders-mo-5a356c91440576fdPharmaRadar360en2026-09-23T00:00:00.000ZDNA methylation dysregulation in EBV-associated lymphoproliferative disorders: molecular mechanisms and therapeutic advanceshttps://www.pharmaradar360.com/article/a-note-on-patient-follow-up-time-distribution-in-clinical-trial-simulations-with-d0133161e4e00572PharmaRadar360en2026-09-23T00:00:00.000ZA note on patient follow-up time distribution in clinical trial simulations with survival endpointshttps://www.pharmaradar360.com/article/clinical-characteristics-treatments-and-outcomes-of-patients-with-ornithine-tran-a1c88d6d32ef3a51PharmaRadar360en2026-09-23T00:00:00.000ZClinical characteristics, treatments and outcomes of patients with ornithine transcarbamylase deficiency (OTCD): a retrospective cohort study using a US electronic health record databasehttps://www.pharmaradar360.com/article/adherence-to-treat-to-target-recommendations-in-juvenile-idiopathic-arthritis-in-84176e3cd58018edPharmaRadar360en2026-09-23T00:00:00.000ZAdherence to treat-to-target recommendations in juvenile idiopathic arthritis in clinical practicehttps://www.pharmaradar360.com/article/precise-repair-of-extremity-soft-tissue-defects-using-anterolateral-thigh-flaps-ec30ab4fc6df8f00PharmaRadar360en2026-09-23T00:00:00.000ZPrecise repair of extremity soft tissue defects using anterolateral thigh flaps based on CTA-based 3D reconstruction and digital design: a short-term retrospective clinical studyhttps://www.pharmaradar360.com/article/beyond-clinical-need-socioeconomic-inequalities-in-access-to-hospital-at-home-am-7c521189ed269087PharmaRadar360en2026-09-23T00:00:00.000ZBeyond clinical need: socioeconomic inequalities in access to hospital at home among older adultshttps://www.pharmaradar360.com/article/i-invited-commentary-on-i-kandathil-et-al-s-postoperative-pain-management-in-rhi-658daec99b991957PharmaRadar360en2026-09-23T00:00:00.000Z<i>Invited Commentary on:</i> Kandathil et al.’s “Postoperative Pain Management in Rhinoplasty: A Double Blind Randomized Controlled Trial”https://www.pharmaradar360.com/article/phenolic-mannich-bases-review-on-synthetic-aspects-and-biological-activity-profi-61a6f71ecb860f68PharmaRadar360en2026-09-23T00:00:00.000ZPhenolic Mannich Bases: Review on Synthetic Aspects and Biological Activity Profileshttps://www.pharmaradar360.com/article/red-blood-cell-aggregation-and-atherosclerosis-curvilinear-clinical-implications-ef768b300cdbacbePharmaRadar360en2026-09-23T00:00:00.000ZRed blood cell aggregation and atherosclerosis: Curvilinear clinical implicationshttps://www.pharmaradar360.com/article/evaluation-of-eating-disorders-in-relation-to-premenstrual-syndrome-in-adolescen-c0244b80e5002d85PharmaRadar360en2026-09-23T00:00:00.000ZEvaluation of Eating Disorders in Relation to Premenstrual Syndrome in Adolescentshttps://www.pharmaradar360.com/article/defining-near-term-treatment-goals-for-benzodiazepine-use-in-clinical-practice-04a3e19325e3d4f7PharmaRadar360en2026-09-23T00:00:00.000ZDefining Near-Term Treatment Goals for Benzodiazepine Use in Clinical Practicehttps://www.pharmaradar360.com/article/the-next-frontier-in-quantitative-co-clinical-imaging-to-advance-functional-prec-ee218ea96855a1a9PharmaRadar360en2026-09-23T00:00:00.000ZThe Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncologyhttps://www.pharmaradar360.com/article/clinical-utility-of-whole-genome-sequencing-in-identifying-a-rare-i-mycobacteriu-94f0e27ffb6f1678PharmaRadar360en2026-09-23T00:00:00.000ZClinical utility of whole-genome sequencing in identifying a rare <i>Mycobacterium</i> species causing native joint infectionhttps://www.pharmaradar360.com/article/clinical-efficacy-and-mechanisms-of-scp-ziyushuang-scp-an-anti-skin-aging-formul-dcb5b530a46d9958PharmaRadar360en2026-09-23T00:00:00.000ZClinical Efficacy and Mechanisms of <scp>ZiyuShuang</scp> , an Anti‐Skin Aging Formula Identified Through Network Medicine Framework Analysishttps://www.pharmaradar360.com/article/comparative-evaluation-of-ambient-digital-scribe-systems-in-clinical-documentati-7e52ee06c03a15d9PharmaRadar360en2026-09-23T00:00:00.000ZComparative evaluation of ambient digital scribe systems in clinical documentationhttps://www.pharmaradar360.com/article/reduced-antibiotic-exposure-is-not-equivalent-to-reduced-antibiotic-overuse-afte-befc1cf0c44de4bfPharmaRadar360en2026-09-23T00:00:00.000ZReduced Antibiotic Exposure Is Not Equivalent to Reduced Antibiotic Overuse After Nirsevimabhttps://www.pharmaradar360.com/article/fully-ablative-co2-laser-excision-of-cutaneous-lesions-a-case-series-including-p-61eadbc7ce6135faPharmaRadar360en2026-09-23T00:00:00.000ZFully ablative CO2 laser excision of cutaneous lesions: A case series including patients with cardiac implantable electronic deviceshttps://www.pharmaradar360.com/article/tolerance-of-methotrexate-co-administered-with-pegloticase-in-patients-with-unco-7f3259a1243d82b3PharmaRadar360en2026-09-23T00:00:00.000ZTolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCThttps://www.pharmaradar360.com/article/the-clinical-benefit-of-routine-pet-ct-imaging-in-asymptomatic-head-and-neck-squ-a01c2272b379ada0PharmaRadar360en2026-09-23T00:00:00.000ZThe clinical benefit of routine PET/CT imaging in asymptomatic head and neck squamous cell cancer patients one year post-treatmenthttps://www.pharmaradar360.com/article/practical-lessons-in-the-global-scaling-of-clinical-ai-from-one-hospital-to-over-d823dc98459196b5PharmaRadar360en2026-09-23T00:00:00.000ZPractical lessons in the global scaling of clinical AI: from one hospital to over a million patients screenedhttps://www.pharmaradar360.com/article/systemic-and-mucosal-antibody-responses-against-neisseria-gonorrhoeae-ng-outer-m-7a0211afbe545718PharmaRadar360en2026-09-23T00:00:00.000ZSystemic and Mucosal Antibody Responses Against Neisseria gonorrhoeae (Ng) Outer Membrane Vesicle Antigens following Four-Component Meningococcal Serogroup B (4CMenB) Immunization in Healthy Adults: A Randomized Phase II Trialhttps://www.pharmaradar360.com/article/comparative-efficacy-and-safety-of-cd19-chimeric-antigen-receptor-t-cell-therapy-bc4ebc4c756dba65PharmaRadar360en2026-09-23T00:00:00.000ZComparative efficacy and safety of CD19 chimeric antigen receptor T-cell therapy versus CD3/CD20 bispecific antibodies in relapsed/refractory mantle cell lymphoma: a meta-analysis of clinical trials and real-world studieshttps://www.pharmaradar360.com/article/synthetic-lethality-in-cancer-mechanisms-therapeutic-exploitation-and-clinical-t-1f3bebf9bae27ae3PharmaRadar360en2026-09-23T00:00:00.000ZSynthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translationhttps://www.pharmaradar360.com/article/asymmetrical-consent-in-ambient-clinical-ai-rethinking-patient-recording-rights-e70ad24154760143PharmaRadar360en2026-09-23T00:00:00.000ZAsymmetrical consent in ambient clinical AI: rethinking patient recording rights and epistemic authority in U.S. health carehttps://www.pharmaradar360.com/article/carotid-intima-media-thickness-in-beta-thalassemia-a-systematic-review-and-meta-305f74b84c51fd60PharmaRadar360en2026-09-23T00:00:00.000ZCarotid Intima-Media Thickness in Beta-Thalassemia: A Systematic Review and Meta-Analysis of Patients Versus Healthy Controls and Clinical–Biochemical Correlateshttps://www.pharmaradar360.com/article/predictors-of-morbidity-and-mortality-in-malignancy-related-ascitic-fluid-infect-d88edb300cf290a3PharmaRadar360en2026-09-23T00:00:00.000ZPredictors of Morbidity and Mortality in Malignancy-Related Ascitic Fluid Infection: an Exploratory Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/pharmacotherapy-of-irritable-bowel-syndrome-with-constipation-in-children-an-upd-afbf506f2debfc3cPharmaRadar360en2026-09-23T00:00:00.000ZPharmacotherapy of Irritable Bowel Syndrome with Constipation in Children: An Update on Clinical Progress and Successeshttps://www.pharmaradar360.com/article/effect-of-preoperative-pain-neuroscience-education-on-pain-catastrophizing-and-e-421cbac901807b13PharmaRadar360en2026-09-23T00:00:00.000ZEffect of preoperative pain neuroscience education on pain catastrophizing and early recovery following upper extremity orthopaedic surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/evaluating-patient-reported-outcome-measurement-in-fibromyalgia-clinical-trials-a645cfade04ad851PharmaRadar360en2026-09-23T00:00:00.000ZEvaluating patient-reported outcome measurement in fibromyalgia clinical trials: a cross-sectional meta-research analysis of alignment with IMMPACT recommendationshttps://www.pharmaradar360.com/article/professional-socialization-and-competency-based-role-development-in-clinical-eth-8af2a02fe55fbcbcPharmaRadar360en2026-09-23T00:00:00.000ZProfessional Socialization and Competency-Based Role Development in Clinical Ethicshttps://www.pharmaradar360.com/article/agentic-ai-in-medicine-challenges-for-responsible-development-and-the-case-for-c-26ffe98b6e3b2465PharmaRadar360en2026-09-23T00:00:00.000ZAgentic AI in Medicine: Challenges for Responsible Development and the Case for Clinical Testing Harnesseshttps://www.pharmaradar360.com/article/performance-status-over-chronology-determinants-of-curative-versus-palliative-tr-13b5296c766e71c2PharmaRadar360en2026-09-23T00:00:00.000ZPerformance status over chronology: determinants of curative versus palliative treatment intent in older adults with gastrointestinal cancerhttps://www.pharmaradar360.com/article/improving-adaptation-in-male-high-altitude-workers-through-pressurization-a-rand-5bafac1786fd222cPharmaRadar360en2026-09-23T00:00:00.000ZImproving adaptation in male high-altitude workers through pressurization: a randomized controlled trial on sleep architecturehttps://www.pharmaradar360.com/article/ranibizumab-port-delivery-system-for-neovascular-age-related-macular-degeneratio-d7aa2ef6ee7adaaePharmaRadar360en2026-09-23T00:00:00.000ZRanibizumab port delivery system for neovascular age-related macular degeneration: Current evidence and surgical considerationshttps://www.pharmaradar360.com/article/procomb-a-practical-and-robust-design-with-randomization-to-optimize-dose-combin-290fbb808edc5459PharmaRadar360en2026-09-23T00:00:00.000ZPROComb: A Practical and Robust Design With Randomization to Optimize Dose Combinations in Drug Combination Trialshttps://www.pharmaradar360.com/article/impact-of-sickle-cell-hemoglobin-genotypes-on-clinical-outcomes-among-i-plasmodi-d38e4ae0b0ee8c10PharmaRadar360en2026-09-23T00:00:00.000ZImpact of Sickle Cell Hemoglobin Genotypes on Clinical Outcomes Among <i>Plasmodium falciparum</i> Malaria Patients in Luanda, Angolahttps://www.pharmaradar360.com/article/from-biological-mechanisms-to-causal-inference-quantitative-systems-pharmacology-3681a18664af4d7ePharmaRadar360en2026-09-23T00:00:00.000ZFrom Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Developmenthttps://www.pharmaradar360.com/article/volumetric-modulated-arc-therapy-for-lung-cancer-correlation-between-dose-and-vo-6490752166bf0195PharmaRadar360en2026-09-23T00:00:00.000ZVolumetric Modulated Arc Therapy for lung cancer: Correlation between dose and volumehttps://www.pharmaradar360.com/article/transvaginal-drainage-vs-laparoscopy-for-tubo-ovarian-abscess-6cbf99995376ed2cPharmaRadar360en2026-09-23T00:00:00.000ZTransvaginal Drainage vs Laparoscopy for Tubo-Ovarian Abscesshttps://www.pharmaradar360.com/article/nct07837336-an-evaluation-of-nutritional-status-body-composition-and-dietary-int-ac0a45c501a1eb6dPharmaRadar360en2026-09-23T00:00:00.000ZNCT07837336: An Evaluation of Nutritional Status, Body Composition, and Dietary Intakes of Filipino Pediatric Patients With Inborn Errors of Intermediary Protein Metabolismhttps://www.pharmaradar360.com/article/nct07837089-increasing-engagement-with-digital-behavioral-health-ef6671fec5e10550PharmaRadar360en2026-09-23T00:00:00.000ZNCT07837089: Increasing Engagement With Digital Behavioral Healthhttps://www.pharmaradar360.com/article/nct07836764-validation-of-1-minute-sit-to-stand-test-for-assessment-of-breathles-8859db9c2c87a48ePharmaRadar360en2026-09-23T00:00:00.000ZNCT07836764: Validation of 1 Minute Sit-to Stand Test for Assessment of Breathlessness at Exertion in Individuals With Chronic Lung Diseasehttps://www.pharmaradar360.com/article/nct07836738-effect-of-stellate-ganglion-block-on-sleep-quality-in-patients-with-5b8e8e776e4c1c8dPharmaRadar360en2026-09-23T00:00:00.000ZNCT07836738: Effect of Stellate Ganglion Block on Sleep Quality in Patients With Depressionhttps://www.pharmaradar360.com/article/nct07836686-clinical-and-radiographic-success-of-modified-lstr-techniques-in-pri-6cb9d89901a63027PharmaRadar360en2026-09-23T00:00:00.000ZNCT07836686: Clinical and Radiographic Success of Modified LSTR Techniques in Primary Second Molarshttps://www.pharmaradar360.com/article/nct07836452-a-phase-1-first-in-human-study-of-city-rbp4-in-healthy-volunteers-an-37c0c1ff6e99544aPharmaRadar360en2026-09-23T00:00:00.000ZNCT07836452: A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participantshttps://www.pharmaradar360.com/article/nct07836439-comparing-graston-technique-and-diacutaneous-fibrolysis-for-pain-dis-e09cd2476cb3651fPharmaRadar360en2026-09-23T00:00:00.000ZNCT07836439: Comparing Graston Technique and Diacutaneous Fibrolysis for Pain, Disability, and Quality of Life in Patients With Non-Specific Low Back Painhttps://www.pharmaradar360.com/article/nct07836205-brain-activity-and-changes-in-consciousness-during-general-anesthesi-b453ee4141f9c01aPharmaRadar360en2026-09-23T00:00:00.000ZNCT07836205: Brain Activity and Changes in Consciousness During General Anesthesiahttps://www.pharmaradar360.com/article/nct07836101-study-of-sarilumab-with-immune-checkpoint-inhibitor-rechallenge-in-p-2356a03863440eaaPharmaRadar360en2026-09-23T00:00:00.000ZNCT07836101: Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Eventshttps://www.pharmaradar360.com/article/nct07836088-a-clinical-study-on-using-multimodal-ultrasound-to-assess-muscle-mas-7d4fef44519e2a4fPharmaRadar360en2026-09-23T00:00:00.000ZNCT07836088: A Clinical Study on Using Multimodal Ultrasound to Assess Muscle Mass in Metabolic Diseaseshttps://www.pharmaradar360.com/article/nct07836036-evaluation-of-ras-inhibitor-treatment-in-participants-with-advanced-97efdfb4531195dbPharmaRadar360en2026-09-23T00:00:00.000ZNCT07836036: Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutationshttps://www.pharmaradar360.com/article/nct07835997-radicle-relaxationtm-cix-a-study-assessing-the-impact-of-health-and-934bffecad7e6f1aPharmaRadar360en2026-09-23T00:00:00.000ZNCT07835997: Radicle Relaxation™ CIX: A Study Assessing the Impact of Health and Wellness Products on Stress and Related Health Outcomeshttps://www.pharmaradar360.com/article/nct07835945-comparison-of-arterial-and-capillary-blood-gas-analyses-in-patients-529f238adbd0acd5PharmaRadar360en2026-09-23T00:00:00.000ZNCT07835945: Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APEhttps://www.pharmaradar360.com/article/nct07830212-diagnostic-performance-of-acp3-targeted-pet-imaging-in-patients-with-565d43acb3c87207PharmaRadar360en2026-09-23T00:00:00.000ZNCT07830212: Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Studyhttps://www.pharmaradar360.com/article/nct07830173-effects-of-task-oriented-training-on-balance-with-or-without-texture-3015b6561b54636cPharmaRadar360en2026-09-23T00:00:00.000ZNCT07830173: " Effects of Task Oriented Training on Balance With or Without Textured Insoles in Patient With Peripheral Diabetic Neuropathy."https://www.pharmaradar360.com/article/nct07825857-randomized-controlled-trial-of-tirzepatide-for-methamphetamine-use-d-23e6cd17cc91d8dfPharmaRadar360en2026-09-23T00:00:00.000ZNCT07825857: Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorderhttps://www.pharmaradar360.com/article/nct07678606-association-between-4d-mri-parameters-and-the-clinical-characteristi-96a7cb0cf013b2e6PharmaRadar360en2026-09-23T00:00:00.000ZNCT07678606: Association Between 4D MRI Parameters and the Clinical Characteristics and Prognosis of Major Chronic Diseaseshttps://www.pharmaradar360.com/article/nct07661810-patient-controlled-remimazolam-sedation-under-spinal-anesthesia-137f2a8674e26ee0PharmaRadar360en2026-09-23T00:00:00.000ZNCT07661810: Patient-controlled Remimazolam Sedation Under Spinal Anesthesiahttps://www.pharmaradar360.com/article/nct07643922-endovascular-therapy-for-cerebral-vasospasm-after-aneurysmal-subarac-8f6d74f8cf9d0947PharmaRadar360en2026-09-23T00:00:00.000ZNCT07643922: Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhagehttps://www.pharmaradar360.com/article/nct07631377-the-lalelalung-study-digital-stethoscope-clinical-evaluation-beb6ad86a49511a4PharmaRadar360en2026-09-23T00:00:00.000ZNCT07631377: The LalelaLung Study: Digital Stethoscope Clinical Evaluationhttps://www.pharmaradar360.com/article/nct07610395-trial-comparing-the-safety-and-efficacy-of-two-different-oral-vpv-do-87a303f89eb88c16PharmaRadar360en2026-09-23T00:00:00.000ZNCT07610395: Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPDhttps://www.pharmaradar360.com/article/nct07549321-a-safety-and-efficacy-study-of-hu14-in-high-risk-neuroblastoma-patie-43b06e17d6f6ecf0PharmaRadar360en2026-09-23T00:00:00.000ZNCT07549321: A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patientshttps://www.pharmaradar360.com/article/nct07530705-efficacy-and-safety-of-subcutaneous-injection-of-xh-02-in-the-treatm-f412cd4960e5cf43PharmaRadar360en2026-09-23T00:00:00.000ZNCT07530705: Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidismhttps://www.pharmaradar360.com/article/nct07527052-emerging-technologies-and-teen-mental-health-1ddeb4440ccb88cfPharmaRadar360en2026-09-23T00:00:00.000ZNCT07527052: Emerging Technologies and Teen Mental Healthhttps://www.pharmaradar360.com/article/nct07522944-ai-guided-personalized-relaxation-for-hemodialysis-patients-a62638bab807b3f4PharmaRadar360en2026-09-23T00:00:00.000ZNCT07522944: AI-Guided Personalized Relaxation for Hemodialysis Patientshttps://www.pharmaradar360.com/article/nct07518407-dietary-insights-and-nutritional-education-in-adults-on-glp-1-therap-4dec0f2fe0a882e7PharmaRadar360en2026-09-23T00:00:00.000ZNCT07518407: Dietary Insights and Nutritional Education in Adults on GLP-1 Therapyhttps://www.pharmaradar360.com/article/nct07502352-remotely-delivered-cognitive-behavioral-stress-management-for-breast-91150ea8bc706ee0PharmaRadar360en2026-09-23T00:00:00.000ZNCT07502352: Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)https://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913PharmaRadar360en2026-09-23T00:00:00.000ZNCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)https://www.pharmaradar360.com/article/nct07343024-methods-of-identifying-effective-off-guideline-treatments-for-advanc-ca2a1b38930bebd7PharmaRadar360en2026-09-23T00:00:00.000ZNCT07343024: Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)https://www.pharmaradar360.com/article/nct07242300-efficacy-and-safety-of-recombinant-botulinum-toxin-type-a-eveotox-fo-045a31d11416acd0PharmaRadar360en2026-09-23T00:00:00.000ZNCT07242300: Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .https://www.pharmaradar360.com/article/nct07237295-communityrx-kidney-health-d9146459a64c0ff2PharmaRadar360en2026-09-23T00:00:00.000ZNCT07237295: CommunityRx-Kidney Healthhttps://www.pharmaradar360.com/article/nct07225075-pivotal-study-of-the-silk-vista-baby-flow-diverters-in-the-treatment-bc87ac8f8819f15dPharmaRadar360en2026-09-23T00:00:00.000ZNCT07225075: Pivotal Study of the Silk Vista Baby Flow Diverters in the Treatment of Unruptured Intracranial Aneurysms (PIONEER)https://www.pharmaradar360.com/article/nct07169630-pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-ad9bf3a66aac9969PharmaRadar360en2026-09-23T00:00:00.000ZNCT07169630: PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)https://www.pharmaradar360.com/article/nct07156175-a-study-to-investigate-the-efficacy-and-safety-of-sar444336-in-adult-b02814ea75fb9a86PharmaRadar360en2026-09-23T00:00:00.000ZNCT07156175: A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remissionhttps://www.pharmaradar360.com/article/nct07094412-patient-engaged-development-and-testing-of-educational-content-on-si-27ba66199a75081ePharmaRadar360en2026-09-23T00:00:00.000ZNCT07094412: Patient-engaged Development and Testing of Educational Content on Side Effects of Statinshttps://www.pharmaradar360.com/article/nct07087249-feasibility-and-preliminary-effects-of-a-therapeutic-approach-using-d219d987db0fd1a3PharmaRadar360en2026-09-23T00:00:00.000ZNCT07087249: Feasibility and Preliminary Effects of a Therapeutic Approach Using Ultrasound Visual Biofeedback in Children With AFI: a Pilot Randomized Clinical Trial.https://www.pharmaradar360.com/article/nct07005297-clinical-genetics-branch-eligibility-screening-survey-e7dec4054d0f1b0fPharmaRadar360en2026-09-23T00:00:00.000ZNCT07005297: Clinical Genetics Branch Eligibility Screening Surveyhttps://www.pharmaradar360.com/article/nct06926283-a-study-of-dxc008-in-patients-with-prostate-cancer-and-other-solid-t-2fa107a99237b6d4PharmaRadar360en2026-09-23T00:00:00.000ZNCT06926283: A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumorshttps://www.pharmaradar360.com/article/nct06922786-hemadsorption-to-enhance-drug-elimination-in-intoxications-84ac6507d560994bPharmaRadar360en2026-09-23T00:00:00.000ZNCT06922786: Hemadsorption to Enhance Drug Elimination in Intoxicationshttps://www.pharmaradar360.com/article/nct06878066-thrombolysis-in-factor-xa-inhibitors-trial-3f17a0f3421a802bPharmaRadar360en2026-09-23T00:00:00.000ZNCT06878066: Thrombolysis in Factor Xa-inhibitors Trialhttps://www.pharmaradar360.com/article/nct06824987-dose-ranging-safety-tolerability-and-efficacy-study-of-azd2373-in-pa-92b855aa8d4ba3faPharmaRadar360en2026-09-23T00:00:00.000ZNCT06824987: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Diseasehttps://www.pharmaradar360.com/article/nct06774885-role-of-folic-acid-in-the-management-of-adjuvant-endocrine-therapy-i-417f6298e18d101cPharmaRadar360en2026-09-23T00:00:00.000ZNCT06774885: Role of Folic Acid in the Management of Adjuvant Endocrine Therapy-Induced Hot Flashes in Breast Cancer Patientshttps://www.pharmaradar360.com/article/nct06659341-a-phase-i-study-of-bay3498264-given-together-with-sotorasib-in-parti-85034d93db98e407PharmaRadar360en2026-09-23T00:00:00.000ZNCT06659341: A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutationhttps://www.pharmaradar360.com/article/nct06633536-real-life-treatment-outcomes-of-ravulizumab-in-pnh-2cd6c195b7a76415PharmaRadar360en2026-09-23T00:00:00.000ZNCT06633536: Real-life Treatment Outcomes of Ravulizumab in PNHhttps://www.pharmaradar360.com/article/nct06630013-a-new-ultrasound-score-for-swallowing-disorders-diagnosis-in-difficu-abb34b6abc54acc3PharmaRadar360en2026-09-23T00:00:00.000ZNCT06630013: A New Ultrasound Score for Swallowing Disorders Diagnosis in Difficult-to-wean Tracheostomised Patientshttps://www.pharmaradar360.com/article/nct06619587-a-study-to-evaluate-safety-pharmacokinetics-and-activity-of-gdc-7035-31c0e9a9b3d7a2cfPharmaRadar360en2026-09-23T00:00:00.000ZNCT06619587: A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct06558214-optimus-prime-safety-and-feasibility-of-optune-gio-integrated-with-m-c4f3b9d8c7fc609ePharmaRadar360en2026-09-23T00:00:00.000ZNCT06558214: OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trialhttps://www.pharmaradar360.com/article/nct06500702-a-study-to-evaluate-the-efficacy-and-safety-of-frexalimab-brivekimig-e8eca76edaae6e69PharmaRadar360en2026-09-23T00:00:00.000ZNCT06500702: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Diseasehttps://www.pharmaradar360.com/article/nct06389591-rna-lipid-particle-rna-lp-vaccines-for-recurrent-adult-glioblastoma-93050016a66deac6PharmaRadar360en2026-09-23T00:00:00.000ZNCT06389591: RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)https://www.pharmaradar360.com/article/nct06305676-biomarker-approach-to-screening-for-the-early-detection-of-hpv-relat-104230ccfe36130bPharmaRadar360en2026-09-23T00:00:00.000ZNCT06305676: Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)https://www.pharmaradar360.com/article/nct06014489-a-trial-to-assess-cobicistat-boosted-venetoclax-in-combination-with-e7d8687b4e0bc8c2PharmaRadar360en2026-09-23T00:00:00.000ZNCT06014489: A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AMLhttps://www.pharmaradar360.com/article/nct05624528-a-clinical-trial-of-tolcapone-in-obsessive-compulsive-disorder-6738dd1b07616e6fPharmaRadar360en2026-09-23T00:00:00.000ZNCT05624528: A Clinical Trial of Tolcapone in Obsessive Compulsive Disorderhttps://www.pharmaradar360.com/article/nct04989504-testing-the-application-of-mepitel-film-during-radiation-therapy-to-a505af7d533aa90cPharmaRadar360en2026-09-23T00:00:00.000ZNCT04989504: Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomyhttps://www.pharmaradar360.com/article/nct04812925-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-efgartigimod-caa7445c3958c388PharmaRadar360en2026-09-23T00:00:00.000ZNCT04812925: A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeniahttps://www.pharmaradar360.com/article/nct04628767-testing-the-addition-of-medi4736-durvalumab-to-chemotherapy-before-s-d432900cd209dde8PharmaRadar360en2026-09-23T00:00:00.000ZNCT04628767: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancerhttps://www.pharmaradar360.com/article/nct04591639-the-dapa-memri-trial-9f8a6fec825fbaa7PharmaRadar360en2026-09-23T00:00:00.000ZNCT04591639: The DAPA-MEMRI Trialhttps://www.pharmaradar360.com/article/nct04433455-influencing-factors-of-cerebrovascular-disease-and-cognition-in-hemo-430cbbfd790ca1dePharmaRadar360en2026-09-23T00:00:00.000ZNCT04433455: Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patientshttps://www.pharmaradar360.com/article/nct04400695-a-study-of-rc48-adc-for-the-treatment-of-locally-advanced-or-metasta-e349c8a3a71c2f58PharmaRadar360en2026-09-23T00:00:00.000ZNCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2https://www.pharmaradar360.com/article/nct04222413-metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors-fba3643f3c2c4144PharmaRadar360en2026-09-23T00:00:00.000ZNCT04222413: Metarrestin (ML-246) in Subjects With Metastatic Solid Tumorshttps://www.pharmaradar360.com/article/nct02444936-zostavax-in-persons-imminently-receiving-chemotherapy-for-solid-orga-ddb176532249fbecPharmaRadar360en2026-09-23T00:00:00.000ZNCT02444936: ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumorshttps://www.pharmaradar360.com/article/rocket-pharmaceuticals-rckt-gets-fda-alignment-on-heart-drug-trial-can-it-ease-s-7185c26cdd11880dPharmaRadar360en2026-09-22T23:52:21.000ZRocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?https://www.pharmaradar360.com/article/keep-britain-working-review-update-a-national-growth-opportunity-september-2026-b449a68a7ec408e5PharmaRadar360en2026-09-22T23:01:04.000ZKeep Britain Working review update: a national growth opportunity, September 2026https://www.pharmaradar360.com/article/as-stigma-fades-reverse-mergers-boom-in-biotech-174a6012d4b759f8PharmaRadar360en2026-09-22T22:59:00.000ZAs Stigma Fades, Reverse Mergers Boom In Biotechhttps://www.pharmaradar360.com/article/fda-takes-issue-with-empower-pharmacy-s-glp-1-production-in-new-warning-letter-bbcc7bc0792288c1PharmaRadar360en2026-09-22T22:48:58.000ZFDA takes issue with Empower Pharmacy's GLP-1 production in new warning letterhttps://www.pharmaradar360.com/article/the-overlooked-role-of-containers-in-chemical-and-pharmaceutical-operations-d9a479d7a99df2f6PharmaRadar360en2026-09-22T22:09:44.000ZThe overlooked role of containers in chemical and pharmaceutical operationshttps://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-pharmaceutical-manufacturing-facility-9c9b191a0f0915cdPharmaRadar360en2026-09-22T21:44:15.000ZEli Lilly Breaks Ground on $6.5B Houston Pharmaceutical Manufacturing Facilityhttps://www.pharmaradar360.com/article/china-s-yipin-pharmaceutical-raises-tens-of-millions-in-yuan-for-anaesthetics-pu-df3f73952434bb15PharmaRadar360en2026-09-22T21:18:04.000ZChina's Yipin Pharmaceutical raises tens of millions in yuan for anaesthetics pushhttps://www.pharmaradar360.com/article/biopharma-biological-safety-cabinets-aseptic-technique-for-sterile-drug-manufact-50ac51026318a92aPharmaRadar360en2026-09-22T20:51:57.000ZBiopharma Biological Safety Cabinets: Aseptic Technique for Sterile Drug Manufacturinghttps://www.pharmaradar360.com/article/vht-vs-xbi-is-diversified-healthcare-exposure-or-biotech-stocks-the-smarter-choi-0db424becee8ba71PharmaRadar360en2026-09-22T20:41:00.000ZVHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors?https://www.pharmaradar360.com/article/amgen-drug-meets-goals-of-key-test-in-common-autoimmune-disease-with-no-approved-562c53f4bdd9952bPharmaRadar360en2026-09-22T20:03:34.000ZAmgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds